91797-58-9

Basic information

• Product Name: Cis-(+/-)-4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Naphthalenamine
• Synonyms: Cis-(+/-)-4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Naphthalenamine;1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-, cis-;Norsertraline hydrochloride
• CAS NO: 91797-58-9
• Molecular Formula: C₁₆H₁₅Cl₂N
• Molecular Weight: 292.203
• Mol File: 91797-58-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 409.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.259±0.06 g/cm3(Predicted)
• PKA: 9.13±0.40(Predicted)
• CAS DataBase Reference: Cis-(+/-)-4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Naphthalenamine(CAS DataBase Reference)
• NIST Chemistry Reference: Cis-(+/-)-4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Naphthalenamine(91797-58-9)
• EPA Substance Registry System: Cis-(+/-)-4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Naphthalenamine(91797-58-9)

Safety Data

• Hazardous Substances Data: 91797-58-9(Hazardous Substances Data)

Upstream product

• 79560-19-3 4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one 
• 95-50-1 1,2-dichloro-benzene 
• 90-15-3 α-naphthol 

Relevant articles and documents

Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis

Resistance phenomena during chemotherapy of tumor has been severely hampering the applications of chemotherapeutics. Due to advantage of drug repurposing, discovery of new chemosensitizers based on approved drugs is an effect strategy to find new candidates. Herein, we found antidepressant drug – sertraline, could sensitize drug-resistant gastric cancer cell (SGC-7901/DDP) with the IC50 value of 18.73 μM. To understand the structure–activity relationship and improve the activity, 30 derivatives were synthesized and evaluated. The IC50 value of the best compound was improved to 5.2 μM. Moreover, we found apoptosis induction and cell cycle arrest was the reason for the cell death of the drug-resistant cells after treatment of sertraline and derivatives, and PI3K/Akt/mTOR pathway was involved.